Last Updated : June 18, 2020
Details
FilesGeneric Name:
certolizumab pegol
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cimzia
Project Line:
Reimbursement Review
Project Number:
SR0587-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Psoriasis, moderate to severe plaque
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
---|---|
Call for patient input posted | October 15, 2018 |
Patient group input closed | December 03, 2018 |
Clarification: - Patient input submission received from the Canadian Association of Psoriasis Patients (CAPP), the Canadian Psoriasis Network (CPN), the Canadian Skin Patient Alliance (CSPA), and Psoriasis Society of Canada | |
Patient input summary sent for review to patient input groups | June 13, 2019 |
Patient group comments on input summary closed | June 20, 2019 |
Clarification: - Patient input summary feedback received | |
Submission received | May 13, 2019 |
Submission accepted | May 28, 2019 |
Review initiated | May 29, 2019 |
Draft CADTH review report(s) sent to sponsor | August 23, 2019 |
Comments from sponsor on draft CADTH review report(s) received | September 04, 2019 |
CADTH review team's comments on draft CADTH review report(s) sent to sponsor | October 03, 2019 |
Canadian Drug Expert Committee (CDEC) meeting | October 16, 2019 |
CDEC recommendation sent to sponsor and drug plans | October 30, 2019 |
Embargo period ended | November 13, 2019 |
CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans | November 20, 2019 |
CDEC Final Recommendation posted | November 22, 2019 |
Redaction requests from sponsor on draft CADTH review report(s) received | December 11, 2019 |
Redacted CADTH review report(s) sent to sponsor and drug plans | December 23, 2019 |
Validation of redacted CADTH review report(s) received | January 07, 2020 |
Final CADTH review report(s) posted | January 29, 2020 |
Files
Last Updated : June 18, 2020